All In Biotech

Drug Trial Radar · NCT07718243

Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC

A Phase I/II Trial of Bexmarilimab and Nivolumab in Patients With Solid Tumours, Non-Small Cell Lung Cancer and Melanoma

Last checked: Nov 19, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

62

Planned (sponsor's estimate)

Start

Aug 28, 2026

Primary completion

Jan 31, 2030

Study completion Jan 31, 2030

Sponsor

Lead sponsor
Institute of Cancer Research, United KingdomAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Faron Pharmaceuticals Ltd; The Christie NHS Foundation Trust; Royal Marsden NHS Foundation Trust
First posted
Jul 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The trial will test if the combination of bexmarilimab and nivolumab can help patients whose cancers have stopped responding to immunotherapy treatment. It will focus on two cancers: non-small cell lung cancer and melanoma. Early research suggests bexmarilimab may change some immune cells inside the tumour so they create a stronger "attack" signal, which could help other immune cells recognise and kill cancer cells more effectively. This may make it easier for PD-1 immunotherapy drugs to work again by helping the immune system stay active against the tumour. This is a Phase I/II clinical trial. In Phase I, researchers will give increasing doses of bexmarilimab together with a standard (fixed) dose of nivolumab to patients with solid tumours, to find the safest and most suitable dose to use going forward (the recommended Phase 2 dose). In Phase II, the study will treat two groups of patients-one with non-small cell lung cancer and one with melanoma-using that selected dose.

Conditions

  • Melanoma (Skin Cancer)
  • Non Small Cell Lung Cancer
  • Solid Tumor in Advanced Stage

Interventions

  • Bexmarilimab 1mg/kg and nivolumab 1mg/kgDrug

    Dose Level 1

  • Bexmarilimab 3mg/kg and nivolumab 1mg/kgDrug

    Dose Level 2

  • Recommended Phase II DoseDrug

    Recommended Phase II Dose of bexmarilimab in combination with nivolumab established from Dose Escalation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To establish a recommended Phase II dose (RP2D) of bexmarilimab in combination with nivolumabTime frame: At the end of Cycle 2 (Cycle 1 is 28 days and Cycle 2 is 21 days)".
  2. Determining causality of each adverse event to bexmarilimab and nivolumab and grading severity according to the NCI CTCAE Version 5.0Time frame: From the start of treatment until the end of the trial (due to documented disease progression or withdrawal of consent or toxicity), with follow-up continuing for 28 days after the last dose of the IMP.
  3. Evaluation of disease response by RECIST criteria version 1.1, immune-modified RECIST (iRECIST) and thus overall response rateTime frame: From date of enrolment until the date of first documented progression, assessed up to 48 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • The Christie NHS Foundation Trust

    Manchester, United Kingdom · Recruiting

  • The Royal Marsden NHS Foundation Trust - Drug Development Unit

    Sutton, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.